Archives: Published Articles

 

In pharma plants, age definitely matters.

 

Ironically, there’s no shortage of new equipment that biotech manufacturers can purchase to replace their older machines. Walk the floor of any HIPAA industry trade show and you can easily get lost in the sea of snazzy new isolators, tablet presses, packaging robots, fill and finish machines — the list goes on. But in a pharma manufacturing plant, this is much more complicated than replacing machinery and plugging in new units out of the box.  In fact, the process can be a regulatory quagmire that companies aren’t likely to emerge from for at least a few years. 

 
 

Manufacturing equipment is also a major investment. It’s no wonder pharmaceutical companies want to put off replacing them to get as much mileage out of their equipment as they can. On top of that, there can be uncertainty involved in trying a new kind of equipment and a learning curve that could lead to production disruptions. Overall, this slow timeline for regulatory approvals and a fear of the unknown creates an environment that makes pharma companies wary of change.

 

 

“When it comes to new Big Pharma tech, no one wants to be the first to implement it — but everybody wants to be the fastest second,” says Maik Jornitz, president and CEO of G-Con Manufacturing, and co-chair of the Parenteral Drug Association’s (PDA) former Aging Facilities Task Force.

 

Yet, there are plenty of compelling reasons to give your aging facilities a needed facelift. Although the regulatory challenges biotech is facing are very real, they’re not insurmountable and can be conquered in a way that’s faster to realize. Also, putting off the process only delays the inevitable breakdown or a regulatory citation that’s likely to be more costly in the long run than an upgrade would have been.

 

Here, we’ll explore the critical link between these manufacturing issues and widespread drug shortages, provide real-world tips on how companies can improve quality control in aging plants, and explain why it pays to update older facilities.

 

Pharma Tech & Drug Shortages

 

The number of drugs and medical supplies in short supply is certainly not a new issue — in the past, the U.S. Food and Drug Administration launched a Drug Shortage Program to help conjure up solutions for keeping a healthy supply of the country’s high-demand medicines. Yet, the problem continues to vex regulators and the industry.

 

Manufacturing technology hiccups that hamper product quality have been shown to be a much bigger culprit of supply problems. The issue is particularly acute in aging facilities where the use of legacy equipment instead of automation often leads to higher rates of contamination.

 

A recent survey conducted by the American Society of Health-System Pharmacists (ASHP) asked pharma manufacturers to identify the cause of shortages, the most-cited known reason was “manufacturing” issues (30 percent). The FDA has also estimated that over half of injectable drug shortages are due to quality problems such as particulate contamination. According to ASHP, the rate of shortages is increasing and “severely impacting patient care and pharmacy operations.”

 

Medicine Manufacturing Compliance

 

Of course, biotechnology companies take calculated measures to remove any deviations that lead to contaminated products. But unfortunately, the economics of producing some types of drugs doesn’t provide incentives for making the needed investments that could help avoid problems with impurities.

 

The product on the FDA’s drug shortage list include a wide range of treatments. They often are the most basic elements for everyday patient care in a health care system (e.g. sterile water, lidocaine, saline, and bupivacaine). These high-demand, older products tend to sku lower on the profit margin scale — making investments into production lines for the drugs less attractive.

 

Pharmaceutical Manufacturing Age

 

There’s no easy way to define what makes a pharma plant officially over the hill. Some experts have estimated that most pharma facilities are designed to run well for about 20 to 25 years. And because all plants are in various states of aging — in regards to both equipment and the facility — it’s difficult to get a handle on how many plants in the U.S. have passed the 20-year mark. But Sue Schniepp, a distinguished fellow with Regulatory Compliance Associates, has seen plenty of first-hand evidence that operations in some plants look like they’re from a bygone era.

 

“The oldest line I’ve seen was about 50 years old,” she explains. “The company had a completely open line, and the only protection was a shower curtain.”

 

 

According to Jornitz, lines that are operating with frequent interventions, such as those susceptible to glass breakage, are at the highest risk of contamination.

 

“It’s important to take the human factor out of the equation,” he says.

 

Jornitz says that the fill lines are often the most vulnerable to contamination issues, but that older utilities, such as outdated water systems, can also put products at risk. Schniepp agrees that contamination risks go beyond equipment.

 

“It’s also in the floors if they’re not state-of-the-art,” she says. “You have to also look at the ceilings — anywhere you’re bringing the walls and ceiling together there’s a gap that could harbor microbes. It’s one thing to put in a restricted access barrier system (RABS). But if there is microbial growth in some of the plant’s older joints, what good have you really done?”

 

Anti-aging for pharma plants

 

Naturally, regular maintenance and upgrades can go a long way in preventing some of these problems.

 

“All facilities are aging,” Jornitz says. “However, when the company is reinvesting funds into the facility and have rigid maintenance or technology improvement cycles, the facility can age much slower.”

 

One of the challenges, however, is that companies are often reluctant or unable to shut down their line to perform maintenance updates.

 

API for Pharma

 

Per the FDA, all APIs are subject to Section 501(a)(2)(B), which requires all drugs to be manufactured in conformance with CGMP. 

 

“When you’re a contract manufacturer especially, sometimes you’re running around the clock,” Schniepp says. “But you have to shut it down to see what’s wearing, what’s tearing — and jump on it before it becomes a problem.”

 

Despite the one-week shutdown that’s typically required for a maintenance check on a company’s line, Schniepp points out that it’s better to spot cracks in the system when it’s down because when it’s running, operations can start to “go awry.”

 

“Look at the line holistically and make sure the equipment is working together,” she says.

 

Jornitz also recommends that companies use predictive maintenance to proactively improve the most important parts of the process steps. Additionally, he says that companies often neglect the importance of their equipment supplier relationships and don’t keep track of the availability of spare parts for their machines.

 

“It’s very important to get early warnings from the supplier that one of their equipment pieces is turning obsolete, so the end-user can act accordingly,” he explains.

 

Pharmaceutical Product Development

 

And putting off these kinds of assessments is likely to haunt pharmaceutical manufacturing companies in the end. Ronald Berk, chief technology officer and principal consultant at Hyde Engineering + Consulting, says that about half of the companies he’s worked with on updating aging facilities are in some kind of regulatory trouble.

 

“We worked for a company that constructed their pharmaceutical manufacturing facility in the late 90s, and the drug they produced was in such high demand that there was a capacity shortage, and they never upgraded the facility,” he recalls.

 

According to Berk, the company didn’t want to slow down production of the drug, so it “hit the snooze button for 20 years,” and never stopped to maintain and improve quality at the facility. Then, after the FDA inspected the facility, the company ended up in a consent decree situation (where the company enters an agreement with the FDA to improve parts of their line that are in violation of regulations). It’s exactly this kind of regulatory scrutiny that should motivate companies to upgrade.

 

Pharmaceutical Manufacturing Success

 

One of the major challenges companies face when dealing with aging facilities is navigating the landscape of regulatory requirements. In particular, companies are reluctant to install new equipment that the FDA could consider a major process modification under its Post Approval Change (PAC) rules. When this occurs, companies often have to revalidate their line, or go through all the tests needed for completing a prior-approval supplement (PAS), which can take as long as four years.

 

In the past, the FDA set out to address this major regulatory hurdle by offering alternative avenues to updating technology. Now, the agency will allow companies to make updates to their operations without a PAS if the new technology is considered a “like for like” change with the older equipment. It’s this route that Schniepp used to completely overhaul the line of one CMO where she worked — a major process she was able to get to the finish line in about two years.

 

“By doing ‘like for like’ you still have to do media fills and qualifications of the line, but you can do it without going through the PAS — as long as you don’t change the footprint of the line,” Schniepp explains. “It would be like upgrading the vanity in your bathroom.”

 

Quality Culture 

 

Here are the major challenges Schniepp faced and how she worked with the QA team to overcome them:

 

Culture and communication: While working as the vice president of Quality for the CMO, Schniepp was tasked with updating a line that was the workhorse of the company, about 30 years old and produced 75 percent of its products. But in the depyrogenation tunnel, the cooling piping was above the products, which was causing fluid to sometimes drip into the vials. The contamination had cost the company approximately $28 million in lost products and triggered an FDA inspection. Yet, Schniepp still faced resistance to change.

 

“When you’re a CMO, your culture is to please the client,” Schniepp says. “When we wanted to upgrade the line, we had to coordinate between about 15 clients that had products on the line and get them all to agree on one approach.”

 

According to Schniepp, not all of the clients thought the “like for like” approach would work. While some were worried about the downtime involved in undergoing a potential PAS, others believed the changes could possibly be communicated to the FDA on an annual reportable. To get everyone on the same page, Schniepp made sure that she wasn’t just talking to the quality department of every pharmaceutical manufacturing client. She also brought each company’s regulatory head into the discussions to get their input and help company leaders feel confident in her plan.

 

Schniepp also ran her plan past the FDA to make sure the agency didn’t have any major concerns with the approach

 

“What regulators really want to see is: Have you thought this out? Can you defend your case? And is your product going to be as safe and effective as it was before? That’s how you win this game,” she says.

 

Working in stages: Once it was time to implement the upgrades, Schniepp says it was all about planning ahead to make sure the company had adequate supplies of its products to offset downtime in operations. The company worked to replace the entire line during a four month period using the comparability protocol specifying before-and-after results for the product requirements for the manufacturing line being replaced.

 

Pharmaceutical Manufacturing QA Training

 

All told, Schniepp says it took a total of two years to update the aging pharmaceutical manufacturing line. Although the company had to deal with about four months of downtime during the process, it was much less of a burden to operations than it would have been to change the entire line under the PAS paradigm.

 

Training: Importantly, Schniepp says the company made sure to adequately train employees with the new equipment so that they could hit the ground running.

 

“We set up the line in a warehouse so the operators could work with it without making any products, because it was so different,” she explains. “They had to learn how to clean the RABS and change out the parts. All of that was going on while we were developing the comparability protocol for shutting down and restarting the line.”

 

Pharmaceutical Manufacturing QA Process

 

Just like when you’re making updates in your home, Berk says that pharma companies often fail to plan for unexpected bumps in the road when revamping their processes and procedures.

 

“One thing that gets underestimated is that if you have an old facility and you start trying to fix things, you might discover other things that need to be fixed or some equipment might break,” he says. “So some kind contingency plan for that is good.”

 

According to Berk, pharmaceutical manufacturing companies also often overlook the life expectancy of their automation and control systems, which can be much shorter than mechanical systems. Changeover to a new control system can also be more challenging than companies realize.

 

“The reality is that you need to spend quite some time testing and qualifying your control system, which can be very time consuming, and inevitably leads to a long downtime,” he explains. “I’ve been at sites where clients wanted to switch overnight. But the process can take up to a month — or half a year if it’s a large facility.”

 

Pharma Tech Outlook

 

There is hope on the horizon in the form of the industry’s newest technologies, if pharma manufacturing companies are willing to adopt them. The rise of automation and single-use equipment, for example, could help lower contamination rates. These advanced technologies allow companies to forgo much of the water utility systems needed to clean stainless steel parts.

 

There could also be changes on the regulatory front and the FDA has demonstrated a commitment to helping companies make needed upgrades.

 

PDA disbanded its Aging Facilities Task Force years ago, but the organization has since launched a new task force aimed at addressing the challenges of Post-Approval Changes. One of the group’s main efforts is to encourage the harmonization of the global regulatory approach to PACs so that companies don’t have to undergo separate approval processes for upgrades in different countries. If other countries accepted an FDA approval, for example, it could shave years off of the process.

 

“The No. 1 question is: How can new, robust technology be implemented faster?” Jornitz explains. “But also, how can we help harmonize global regulations?”

 

Continuous Improvement

 

But for too long, Jornitz says that the industry has used this regulatory hurdle as an excuse for not updating their facilities.

 

“Ultimately, running assets until they break down will cost much more than continuous improvements,” Jornitz argues. And when it comes to dealing with the red tape, Jornitz says that companies that are updating aging tech have a strong case to make with regulators. If they can show that new technology improves patient safety and avoids drug shortages, I think regulators will listen,” he says.

 

To begin the Regulatory Compliance Associates scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage. You may also email us at [email protected].

 
Q. I have just been promoted to be in charge of investigations for my company. Our standard operating procedure (SOP) requires us to complete an FDA investigation in 30 days. Depending on the nature of the investigation and to meet the SOP requirement, I have started to close investigations at the 30-day time point even though I think the investigation might not be complete. Sometimes I have had to re-open investigations because the problem recurs, confirming that the investigation was not completed. Do I have a compliance risk if I continue with this practice?

 

A. The short answer is yes, you have a compliance risk. You probably also have a data integrity issue and a quality culture issue to accompany your compliance risk. There is no time element associated with conducting an internal investigation. Thirty days is an arbitrary number pharmaceutical companies impose on themselves. There are very specific deadlines associated with an FDA investigation you need to pay close attention to.

 

The US Code of Federal Regulations states

 

“… if errors have occurred, that they have been fully investigated” (1), and “Any unexplained discrepancy … shall be thoroughly investigated, whether or not the batch has already been distributed”

 

Europe’s EudraLex also addresses investigations by stating,

 

“An appropriate level of root cause analysis should be applied during the investigation of deviations …”.

 

None of these citations indicate a time for completion of an investigation. What they do imply is that investigations need to be thorough and determine root cause. In some cases, the investigation and root cause can be easily determined in the defined SOP time frame of 30 days.

 

In other cases, the investigation may be more complicated and could exceed the time frame requirement of 30 days. To address this potential discrepancy, your SOP should allow for FDA investigation extensions if possible. The length of the extension request should be made based on the complexity of the investigation.

 

FDA Pharma Regulations

 

When an investigation is rushed, the organization leaves itself vulnerable. Suppose, for example, you have a second shift manufacturing operator who continually forgets to sign a step in the batch record for a specific product. This operator is the only one who seems to have this issue. Your initial investigation into the first occurrence of the issue determines a root cause of human error.

 

Because the operator works on the second shift, it is inconvenient to interview him directly, so you rely on the word of his supervisor that this was just a case of human error. You decide to retrain the operator on the proper use of filling out the form and skip the operator interview in order to complete the investigation and perform the retraining in the allotted 30-day time frame.

 

FDA Observation

 

A few weeks later, the same operator makes the same mistake. You review the previous investigation, arrive at the same conclusion, and perform the retraining of the operator emphasizing the importance of correctly filling out the batch record. This scenario repeats itself 10 times over the course of four months. You finally decide to question the ability of the operator to do the job correctly and bring your concerns to management that this behavior could lead to an FDA observation.

 

Your boss asks if anyone has interviewed the operator directly to find out why he is having this issue with the batch record. You say no, that you have relied on the opinion of the supervisor. The boss recommends you interview the operator before demoting him.

 

FDA Audit

 

When you talk to the operator, he informs you that in order to sign the batch record when it needs to be signed, he needs to exit the aseptic core, degown, sign the batch record, and regown, leaving the product unattended during that time.

 

The operator tells you he chose to stay with the product and sign the batch record later but sometimes forgot after the manufacturing run. In this simple exchange with the operator you realize that the root cause of the repeat deviation is not a result of human error but a result of poor process flow. These are the kind of mistakes an FDA investigator will definitely find during an FDA audit of a pharmaceutical manufacturer. 

 

Gap Analysis

 

The question you need to address now is how were other operators handling the situation? Only by understanding how widespread the issue is can you conduct an accurate gap assessment. By not taking the time to perform the initial investigation thoroughly, you have created a data integrity nightmare because you now need to review all the batch records completed by the other operators to determine if the product is still acceptable.

 

Admittedly, this is a simplistic example, but it certainly exemplifies the importance of opting to perform a complete and thorough investigation over meeting an artificially imposed time frame. Explaining to an inspector during an audit that you didn’t perform a thorough investigation because you needed to meet an arbitrary time frame is not a position you want your company to be in. You also don’t want to explain why you closed an investigation to meet the time frame and then felt compelled to reopen it after the batch was released because you had concerns about its conclusions.

 

FDA GMP

 

The other element that needs to be addressed is that of the prevalent culture existing in the organization. It is good to set a time goal for FDA compliance activities performing investigation, thus ensuring their timely completion. It is not acceptable to have the time frame be the driving force behind the investigation.

 

Management needs to emphasize their commitment to having thorough investigations as opposed to being unprepared for an FDA investigation. It is ideal when an investigation is completed and a true root cause identified in the specified time frame but, if that is not achievable, management needs to be clear that they prefer the identification of the true root cause over the rushed investigation that merely checks the box for completion in a timely manner. Without this management commitment, the premature closing of investigations will likely continue.

 

Good Manufacturing Practices

 

Investigations need to focus on determining root cause in a timely manner. The length of time it takes to complete an investigation depends on the complexity of the investigation. The primary driver for avoiding compliance and data integrity risks concerning investigations is arriving at a root cause in a timely manner. This allows you to be confident in presenting your investigations during inspection and avoiding unnecessary scrutiny when the investigation is rushed and a conclusion is reached prematurely.

 

regulatory compliance

 

Pharmaceutical Technology
Volume 42, Issue 12, pg 50, 49

 

To begin the Regulatory Compliance Associates scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage. You may also email us at [email protected].

Deviation investigations are an essential part of maintaining pharmaceutical quality and cGMP compliance. In this Ask the Expert discussion, Susan J. Schniepp and Steven J. Lynn of Regulatory Compliance Associates explain how organizations should identify, investigate, and resolve deviations to understand what went wrong, determine the underlying causes, and prevent recurrence. Although deviations can vary in severity and impact, all should be investigated.

 

The experts emphasize that investigations should be proportionate to the issue rather than follow a one-size-fits-all approach. Simple events may require straightforward documentation, while more complex deviations warrant broader investigations. They also caution against relying on “human error” as a root cause without further examination. Repeated errors may point to underlying problems with procedures, process design, workflow, or training. Asking the right questions, interviewing involved personnel, and verifying assumptions with supporting data can help identify the true source of a problem.

 

The discussion also addresses planned deviations, investigation timelines, and out-of-specification (OOS) results. Rather than using planned deviations to justify temporary departures from procedures, the experts recommend documenting necessary procedural changes through the change control system and evaluating their impact. Investigation timelines should reflect the complexity of the event, with 30 to 60 days offered as a potential timeframe. OOS results should be investigated separately and promptly, with a deviation initiated when laboratory error cannot explain the result. Ultimately, effective deviation management depends on thorough investigations, sound root cause analysis, and corrective actions that strengthen the quality system.

 

Read the full article: Frequently Asked Questions on Deviations

What is a CDMO?

A CDMO is a Contract Development and Manufacturing Organization. These are companies in the pharmaceutical, biotechnology, and medical device industries that provide outsourced services to other companies, typically pharmaceutical or biotech firms.

 

Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, discusses the basics for maintaining an acceptable working relationship between a client and their CDMO.

 

Q. I work for a small company with a few products in the development phase. I am reviewing several CDMO (contract development and manufacturing organizations) partners to determine which one best fits our needs. Can you give me some general guidance on what I should look for when choosing an appropriate partner?

 

A. Contract manufacturing continues to be one of the fastest growing segments of the pharmaceutical industry. There are many small companies with products in development who do not own manufacturing facilities and must utilize CDMO partners to handle their development and manufacturing needs from clinical to commercial product. It is important for both parties to be invested and respectful in the relationship because it is a long-term commitment.

 

Contract Manufacturing Organization

 

The first step in this relationship is to establish a quality agreement (1–3). If we view the relationship between the two parties as an equation it would be:

A + B + C + D = E

 

regulatory compliance

A represents needs of the CDMO, B represents the client needs, C represents the compliance requirements, D represents the regulatory commitments for both parties, and E represents the quality agreement/quality relationship between the two organizations.

 

CDMO Services

 

As we break the equation down a bit more, there there is more CDMO meaning behind each of the variables.

 

“Variable A” should take into account the needs of the CDMO. This includes auditing, testing, material sourcing, and any special client needs required to successfully manufacture the product. When defining the contract development organization responsibilities, the CDMO should consider determining the amount of involvement of the client(s) for all audit types.

 

CDMO Manufacturing

 

“Variable B” represents the client needs and should take into consideration unique account requirements. For example, there will be differences between a Biopharma CDMO, a Biologics CDMO and CDMO Pharma companies. This often includes data driven development, USFDA registration commitments and specific sourcing strategies. The client should also inform the CDMO of any additional quality agreements that are associated with pharmaceutical manufacturing.

 

At one point in my career, I worked for a small start-up company which had three quality agreements associated with one product in clinical trials. The three agreements were for three different contract organizations. One CDMO organization was manufacturing the material, another was performing the release testing, and the final one was performing the product labeling. These complicated relationships should be disclosed to all involved parties so communication between organizations can be optimized, particularly when issues arise.

 

Compliance

 

“Variable C” represents compliance requirements of the CDMO. This is often influenced by multiple customers, regulatory agencies, and regulatory bodies. Company standard operation procedures (SOPs) (4–6), client SOPs, audit observations, and compendial requirements define this element of our equation. Clients should be aware that CDMOs are usually global in nature and may have obligations to meet compendial requirements of the United States Pharmacopeia–National Formulary (USP–NF), the European Pharmacopoeia (Ph.Eur.), and the Japanese Pharmacopoeia (JP) (7).

 

In my opinion, this would be the optimal section to include the communication expectations for regulatory audits conducted either at the CDMO or the client’s business locations. The need for the CDMO to communicate with the client when a regulatory audit is being performed at their facility is evident, but it is equally important that the client communicates with the CDMO when the positions are reversed. This two-way communication is crucial because each organization could be vulnerable based on the audit outcome regardless of where the audit was conducted.

 

Regulatory

 

The final variable in this equation is “Variable D”. Variable D considers the regulatory commitments of the client and/or the CDMO. Regulatory commitments are the evolving body of knowledge made up of new or impending regulations or guidelines that may require changes in operations in order to meet the expectations of the new requirements. A CDMO must communicate changes and commitments affecting their quality system to their client and vice versa because these changes may affect regulatory filings.

 

Quality

 

Finally, the solution to the equation is “Variable E”, which represents the robust quality agreement. The quality agreement should be a living, breathing document that is reviewed and revised as often as needed to clarify both party’s responsibilities and avoid conflict of responsibilities to ensure a successful partnership.

 

Contract Manufacturing

 

The relationship between the client and the CDMO is important and complex. Both parties need to be knowledgeable on the application and interpretations of the regulations. Each should work through any opposing opinions to reach an interpretation that works for both parties. A cooperative working relationship can be achieved if each party clearly identifies and communicates their needs through an effective quality agreement.

 

Article details

 

regulatory compliance

 

 

 

 

 

Pharmaceutical Technology
Vol. 46, No. 6
Page: 50

 

To begin the Regulatory Compliance Associates scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage. You may also email us at [email protected].

The amount of quality assurance detail included in Standard Operating Procedures (SOP) may help a company stay QA compliant, says Susan J. Schniepp, Distinguished Fellow at Regulatory Compliance Associates, Inc.

 

Q. I am responsible for updating my company’s standard operating procedures (SOPs). My company has been cited several times in audits for not following them, and this situation has worsened since the onset of the pandemic. What advice do you have for me to make sure the SOPs are being followed for now and in the future?

 

A. You are not alone. Not following or having adequate procedures in writing continues to be one of the top SOP observations for the industry in 2021. Companies usually use their SOP to show that they have control over manufacturing processes, thereby demonstrating compliance with regulatory expectations. Both QA testing and QA engineering have even more stringent expectations in SaMD (software as a medical device) products. 

 

The problem you are having with your SOPs seems to be an ongoing issue not necessarily related to the pandemic. It would seem this situation is exacerbated by the pandemic but not caused by the pandemic. My advice to you would be to take a holistic look at how you create, implement, and modify your SOPs.

 

SOP Compliance

 

There are four simple concepts to keep in mind for having compliant SOPs: Say what you do, do what you say, prove it, improve it. The ‘say what you do’ phrase equates to the written SOP that defines the steps to achieve compliance to a regulatory requirement.

 

‘Do what you say’ equates to following the SOP. ‘Prove it’ means that you need to collect and be able to present data that indicate you have followed the instructions in your SOP and have investigated any incidents where you have deviated from those instructions.

 

SOP Process Improvements

 

Once you have mastered these concepts, you can begin to work on the ‘improve it’ concept by revising and updating your SOPs to reflect current practice and process improvements. These concepts are simple enough to follow, so the being cited by regulators for not following SOPs is disappointing.

 

Previously in this column, we have discussed the elements of Standard Operating Procedures. The problem you are having seems to be related to the SOP content.

 

SOP Writing

 

To address this particular problem, you need to be aware of some of the pitfalls companies encounter when writing SOPs. Writing an SOP with the correct amount of information in it—neither too restrictive nor too ambiguous—is not an easy task. It takes time and effort to create an SOP with the right balance of information.

 

SOP Pitfalls

 

The three most common pitfalls when writing an SOP are providing too much information, providing too little information, and providing unneeded specific information. Quality assurance is always built upon a foundation of clear and concise data. Quality control engineering necessitates that a quality assurance inspection would fail without it. 

 

Providing too much information in Standard Operating Procedures results in a restrictive process with deviations. An example of too much information in an SOP would be listing the serial number for a piece of equipment. Should the piece of equipment need to be changed for any reason, the result is a deviation and an SOP that can’t be followed.

 

Equipment SOP 

 

When listing equipment requirements in an SOP, a Quality Analyst should be able to describe the piece of equipment but not necessarily to the serial number. It would be best to provide a list of the equipment needed with a general description of its function and capability. Additionally, the QA Manager should have a deeper level of knowledge about the QA process and be able to speak to the equipment validation.

 

FDA inspection SOPWhen an SOP provides too little information, it results in an out-of-control operating process that generates deviations. When there is lack of clarity, it allows for interpretation by the operator.

 

SOP Operators

 

There is the potential for each individual executing the process to interpret the instructions in their own unique way resulting in deviations that need to be investigated and the potential for the regulatory citation of insufficient SOPs.

 

An example of a quality assurance program with too little information for operators includes not specifying the order reagents need to be added to generate a reaction. If it is critical to add the reagents in a certain order, that information needs to be specified in the Standard Operating Procedures.

 

SOP Information

 

Quality control plans with SOPs that provide unneeded specific information are also problematic. An example of unneeded specific information might be how dates are recorded in a document. A company needs to be consistent in the way the date is recorded. The order of the day, month, and year can be flexible regarding the information being separated by hyphens or slashes. There is no difference between DD/MM/YY and DD-MM-YY. Specifying hyphens versus slashes sets you up for deviations that waste time and resources.

 

Other potential pitfalls for QA teams to avoid are providing ambiguous information. Similarly, restricting access to SOPs or allowing access to obsolete SOPs can lead to data integrity issues. Finally, having unnecessary SOPs or not providing clear instructions for recording data inhibits the culture of quality.

 

Effective SOP

 

Writing effective Standard Operating Procedures and keeping it current is not an easy task. It requires time, effort, and cooperation with the users to achieve the correct balance. Both quality control and quality assurance take time to develop and improve toward the end state. 

 

Employees must use a process that is easily followed, specifies the correct data, records the current operations, and can be improved. Taking a critical look at the level and detail provided in your SOPs involves right sizing the information. For example, accurately reflecting your operations will help in eliminating an audit observation. Above all, not following SOPs or having insufficient SOPs must be addressed to help improve your compliance position.

 

Article Details

Pharmaceutical Technology
Volume 44, Number 10
Pages: 74, 73

 

To begin the Regulatory Compliance Associates scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage. You may also email us at [email protected].

Extractables and leachables (E&L) assessments play an important role in demonstrating that pharmaceutical products, packaging components, and manufacturing materials are suitable for their intended use. In this Ask the Expert article, Susan J. Schniepp of Regulatory Compliance Associates explains when companies should evaluate and submit E&L data to regulatory authorities. Although regulatory requirements establish the need to ensure that containers, closures, and manufacturing equipment do not adversely affect product quality or safety, there is no single rule defining when E&L information must be submitted.

 

The timing depends on several factors, including the type of product, its formulation, packaging materials, and manufacturing processes. For example, generic products using the same active ingredients and packaging components as an approved reference product may be able to provide E&L information later in development. In contrast, novel products, reformulated products, biologics, combination products, and products using unique packaging or single-use manufacturing systems may require earlier evaluation. Manufacturing equipment such as filters and tubing should also be considered as potential sources of extractables and leachables.

 

Schniepp emphasizes the value of conducting a risk evaluation early in development to determine when E&L data should be generated and made available to regulators. By identifying potential sources of leachables and assessing their impact on product quality and patient safety, companies can better plan their testing and regulatory submissions. A proactive approach helps reduce the risk of regulatory delays and supports a smoother product approval process.

 

Read the full article: Submitting Extractables and Leachables Data to Regulators